InMode Ltd

NASDAQ INMD

Download Data

InMode Ltd Equity Multiplier 5 year CAGR for the quarter ending March 31, 2024: -7.08%

InMode Ltd Equity Multiplier 5 year CAGR is -7.08% for the quarter ending March 31, 2024. The Equity Multiplier measures the proportion of a company's assets that are financed by equity. It indicates the level of financial leverage in a company's capital structure. A higher ratio suggests a higher level of debt financing and indicates higher financial risk. The equity multiplier is useful in assessing the company's solvency and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • InMode Ltd Equity Multiplier for the quarter ending March 31, 2023 was 1.11, a -3.57% change year over year.
  • InMode Ltd Equity Multiplier for the quarter ending March 31, 2022 was 1.15, a -0.22% change year over year.
  • InMode Ltd Equity Multiplier for the quarter ending March 31, 2021 was 1.15, a -3.98% change year over year.
  • InMode Ltd Equity Multiplier for the quarter ending March 31, 2020 was 1.20, a -23.86% change year over year.
NASDAQ: INMD

InMode Ltd

CEO Mr. Yair Malca
IPO Date Aug. 8, 2019
Location Israel
Headquarters Tavor Building, Yokne'am, Israel, 2069206
Employees 581
Sector Healthcare
Industry Medical devices
Description

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Similar companies

ABT

Abbott Laboratories

NA

NA

MDT

Medtronic PLC

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email